Skip to main content

Advertisement

Table 2 Disease distribution and Clinical results

From: Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer

Patients (n) Disease type CB = n (%) DoCB in months DoT in months
All (n = 17) 14 MBC 3 LAPC 10 (58.8%); 1PR,9SD (8 MBC & 2 LAPC) 10+ (7-27) 9+ (1-27)
Tamoxifen (n = 10) 9 MBC 1 LAPC 6 (60%); 1 PR, 5 SD (6 MBC) 10.5+ (7-27) 8.5+ (1-27)
Rest (n = 7) 1M,1F,4E,1L 5 MBC 2 LAPC 4 (57.1%); 4 SD (2 MBC & 2 LAPC) 9.5+ (9-23) 9+ (2-23)
  1. M = Megestrol acetate; F = Fulvestrant; E = Exemestane; L = Letrozole; MBC = Metastatic Breast Cancer; LAPC = Locally Advanced Primary Breast Cancer; PR = Partial Response; SD = Stable Disease; DoCB = Duration of Treatment in patients with Clinical Benefit; DoT = Duration of Treatment irrespective of response